AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD
5.63
-0.14 (-2.43%)
At close: Oct 28, 2025, 4:00 PM EDT
5.65
+0.02 (0.36%)
After-hours: Oct 28, 2025, 6:45 PM EDT
-2.43%
Market Cap1.68B
Revenue (ttm)32.88M
Net Income (ttm)-165.67M
Shares Out 298.83M
EPS (ttm)-0.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,757,229
Open5.76
Previous Close5.77
Day's Range5.56 - 5.76
52-Week Range1.89 - 6.52
Beta0.69
AnalystsStrong Buy
Price Target8.00 (+42.1%)
Earnings DateNov 6, 2025

About ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 596
Stock Exchange NASDAQ
Ticker Symbol ABCL
Full Company Profile

Financial Performance

In 2024, AbCellera Biologics's revenue was $28.83 million, a decrease of -24.17% compared to the previous year's $38.03 million. Losses were -$162.86 million, 11.2% more than in 2023.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 42.10% from the latest price.

Price Target
$8.0
(42.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.

21 days ago - Business Wire

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivo...

22 days ago - Seeking Alpha

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025.

4 weeks ago - Business Wire

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.

6 weeks ago - Business Wire

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575.

2 months ago - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in September

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in September.

2 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chair...

2 months ago - Seeking Alpha

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms.

2 months ago - Business Wire

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025.

4 months ago - Business Wire

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.

5 months ago - Business Wire

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.

5 months ago - Business Wire

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit.

6 months ago - Business Wire

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025.

6 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief...

6 months ago - Seeking Alpha

AbCellera Reports Q1 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2025 Business Results.

6 months ago - Business Wire

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.

6 months ago - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in May and June

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in May and June.

7 months ago - Business Wire

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025.

7 months ago - Business Wire

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025.

7 months ago - Business Wire

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executi...

8 months ago - Seeking Alpha

AbCellera Reports Full Year 2024 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2024 Business Results.

8 months ago - Business Wire

AbCellera to Participate at Upcoming Investor Conferences in March

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in March.

9 months ago - Business Wire

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2024 Financial Results on February 27, 2025.

10 months ago - Business Wire

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology.

10 months ago - Business Wire

AbCellera Biologics: Still A Concept Stock

Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partne...

11 months ago - Seeking Alpha